CLINICAL TRIALS PROFILE FOR MINIPRESS

All Clinical Trials for Minipress

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00161473 ↗	Alzheimer's in Long-Term Care--Treatment for Agitation	Completed	National Institute on Aging (NIA)	N/A	2001-01-01	The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.
NCT00161473 ↗	Alzheimer's in Long-Term Care--Treatment for Agitation	Completed	University of Washington	N/A	2001-01-01	The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.
NCT00175682 ↗	Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study	Completed	University of British Columbia	N/A	2004-12-01	Sexuality is a high rehabilitative priority for persons following a spinal cord injury (SCI). Sexual acts can lead to autonomic dysreflexia (AD), dangerous consequences such as a sudden increase in blood pressure, severe headache, sweating above the level of the lesion and low heart rate to name a few. Ejaculation in men can provoke these significant symptoms and therefore men and women may refrain from a sexual life and biological parenthood. Adalat is the most common antihypertensive used in fertility clinics to reduce the incidence of AD. It dramatically reduces blood pressure and, therefore, results in side effects such as dizziness, fatigue and weakness. The investigators hypothesize that Minipress® (prazosin HCL), a blood pressure medication, which has a slower and less abrupt suppressive effect on blood pressure, would be a safe, effective and more appropriate medication for use in the outpatient sperm retrieval clinic and potentially for private use.
NCT00183430 ↗	Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder	Terminated	National Institute of Mental Health (NIMH)	N/A	2003-10-01	This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.
NCT00183430 ↗	Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder	Terminated	Seattle Institute for Biomedical and Clinical Research	N/A	2003-10-01	This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.
NCT00202449 ↗	Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance	Terminated	United States Department of Defense	N/A	2004-07-01	The purposes of this study are: - to evaluate the efficacy and tolerability of the drug prazosin compared to placebo for combat stress-related nightmares, sleep disturbance and overall function in recently combat-exposed returnees from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF). - to evaluate the effects of the selective serotonin reuptake inhibitor (SSRI) paroxetine on behavioral symptoms and overall function in this population.
NCT00202449 ↗	Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance	Terminated	VA Puget Sound Health Care System	N/A	2004-07-01	The purposes of this study are: - to evaluate the efficacy and tolerability of the drug prazosin compared to placebo for combat stress-related nightmares, sleep disturbance and overall function in recently combat-exposed returnees from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF). - to evaluate the effects of the selective serotonin reuptake inhibitor (SSRI) paroxetine on behavioral symptoms and overall function in this population.

Clinical Trial Conditions for Minipress

Condition Name

Condition Name for Minipress
Intervention	Trials
Posttraumatic Stress Disorder	5
Alzheimer's Disease	2
Hypertension	2
Stress Disorders, Post-Traumatic	2

Condition MeSH

Condition MeSH for Minipress
Intervention	Trials
Stress Disorders, Post-Traumatic	9
Stress Disorders, Traumatic	7
Disease	7
Alcoholism	6

Clinical Trial Locations for Minipress

Trials by Country

Trials by Country for Minipress
Location	Trials
United States	32
Canada	3

Trials by US State

Trials by US State for Minipress
Location	Trials
Washington	14
Connecticut	3
California	2
Texas	1
South Carolina	1

Clinical Trial Progress for Minipress

Clinical Trial Phase

Clinical Trial Phase for Minipress
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Phase 2	7

Clinical Trial Status

Clinical Trial Status for Minipress
Clinical Trial Phase	Trials
Completed	13
Recruiting	7
Active, not recruiting	2

Clinical Trial Sponsors for Minipress

Sponsor Name

Sponsor Name for Minipress
Sponsor	Trials
Seattle Institute for Biomedical and Clinical Research	7
VA Puget Sound Health Care System	7
VA Office of Research and Development	4

Sponsor Type

Sponsor Type for Minipress
Sponsor	Trials
Other	29
U.S. Fed	15
NIH	8

MINIPRESS (Prazosin HCl): Clinical Trials, Market Analysis, and Projections

Introduction to MINIPRESS

MINIPRESS, also known as prazosin hydrochloride, is a medication primarily used for the treatment of hypertension and other conditions such as post-traumatic stress disorder (PTSD). Here, we will delve into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Hypertension Treatment

MINIPRESS is well-established for its efficacy in lowering blood pressure, thereby reducing the risk of fatal and nonfatal cardiovascular events like strokes and myocardial infarctions. Clinical trials have shown that controlling high blood pressure with MINIPRESS, as part of comprehensive cardiovascular risk management, is crucial for patient health[1].

Dosing and Administration

Clinical trials emphasize the importance of careful dosing to minimize adverse effects. The initial dose should be limited to 1 mg, with subsequent slow increases to avoid syncopal episodes. Patients receiving beta-blockers, such as propranolol, should be monitored for hypotension[1].

Other Clinical Uses

There is ongoing interest in the potential of prazosin for other clinical applications. For example, researchers have suggested its use in preventing lethal complications of COVID-19, although this requires further controlled clinical trials to establish safety and efficacy[4].

Market Analysis

Current Market Size and Growth

The prazosin hydrochloride market was valued at USD 1.15 billion in 2022 and is projected to reach USD 1.78 billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030. This growth is driven by the increasing prevalence of hypertension and PTSD, as well as growing awareness of prazosin's potential applications beyond its traditional use[2].

Geographical Distribution

The market expansion is particularly significant in North America and Europe, where the demand for antihypertensive medications and therapeutics for psychiatric conditions is high. Emerging economies are also expected to contribute to the market growth due to rising disposable incomes and urbanization[2].

Market Dynamics

The market is influenced by several factors, including the increasing prevalence of hypertension and PTSD, developing technologies, and growing applications. Sustainability trends and legislative support are also expected to drive the market forward. However, the market faces restraints such as potential side effects and the need for careful dosing and monitoring[5].

Future Projections

Market Forecast

The prazosin hydrochloride market is expected to continue growing, driven by rising consumer demand and developing technologies. The market is forecasted to expand in both developed and emerging economies, with a focus on sustainability and legislative backing[2].

New Applications and Research

There is ongoing research into new applications of prazosin, including its potential use in preventing complications from viral illnesses. However, these novel uses require further clinical trials to establish their safety and efficacy[4].

Economic Impact

The global and Chinese macroeconomic environment will play a significant role in the future of the prazosin market. Economic trends, including global and Chinese macroeconomic analyses, will influence the market's development and growth[5].

Adverse Effects and Safety

Common Adverse Reactions

Clinical trials and post-marketing experience have identified several common adverse reactions associated with MINIPRESS, including dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. Most of these side effects are self-limiting and do not require a decrease in the dose of the drug[1].

Less Frequent Adverse Reactions

Less frequent adverse reactions include gastrointestinal issues, cardiovascular effects such as edema and orthostatic hypotension, central nervous system effects like vertigo and depression, and dermatologic reactions like rash[1].

Key Takeaways

• Clinical Trials: MINIPRESS is well-established for hypertension treatment, with careful dosing and monitoring recommended to minimize adverse effects.
• Market Growth: The prazosin hydrochloride market is projected to grow significantly, driven by increasing prevalence of hypertension and PTSD, and expanding into new applications.
• Future Projections: The market is expected to continue growing, influenced by consumer demand, technological developments, and sustainability trends.
• Adverse Effects: Common and less frequent adverse reactions have been identified, emphasizing the need for careful patient monitoring.

FAQs

What is MINIPRESS primarily used for?

MINIPRESS is primarily used for the treatment of hypertension to lower blood pressure and reduce the risk of cardiovascular events.

What are the common adverse reactions associated with MINIPRESS?

Common adverse reactions include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea.

What is the projected market size of prazosin hydrochloride by 2030?

The prazosin hydrochloride market is projected to reach USD 1.78 billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030.

Are there any new potential applications of MINIPRESS being researched?

Yes, researchers are exploring the potential use of prazosin in preventing lethal complications of COVID-19 and other viral illnesses, although further clinical trials are needed.

How does the dosing of MINIPRESS need to be managed to minimize adverse effects?

The initial dose of MINIPRESS should be limited to 1 mg, with subsequent slow increases to avoid syncopal episodes, especially in patients receiving beta-blockers.

Sources

1. Pfizer Medical Information - US: MINIPRESS® (prazosin HCl)
2. GitHub: Prazosin Hydrochloride Market Key Drivers and Forecast 2025-2032
3. Marinus Pharmaceuticals: Update on the Phase 3 RAISE Trial and Q1 2024 Financial Results
4. Johns Hopkins Medicine: Researchers Urge Clinical Trial of Blood Pressure Drug to Prevent Lethal Complication of COVID-19
5. Prof Research: Prazosin Market Size, Share, Trend and Forecast to 2025

Last updated: 2025-01-06